Entry and Competition in Generic Biologics
Managerial and Decision Economics, 2007
39 Pages Posted: 17 Jul 2007 Last revised: 20 Sep 2014
Abstract
Patents for several blockbuster biological products are expected to expire soon. The Food and Drug Administration is examining whether biologics can and should be treated like pharmaceuticals with regard to generics. In contrast with pharmaceuticals, which are manufactured through chemical synthesis, biologics are manufactured through fermentation, a process that is more variable and costly. Regulators might require extensive clinical testing of generic biologics to demonstrate equivalence to the branded product. The focus of the debate on generic biologics has been on legal and health concerns, but there are important economic implications. We combine a theoretical model of generic biologics with regression estimates from generic pharmaceuticals to estimate market entry and prices in the generic biologic market. We find that generic biologics will have high fixed costs from clinical testing and from manufacturing, so there will be less entry than would be expected for generic pharmaceuticals. With fewer generic competitors, generic biologics will be relatively close in price to branded biologics. Policy makers should be prudent in estimating financial benefits of generic biologics for consumers and payers. We also examine possible government strategies to promote generic competition.
Keywords: generic, biologic, biological
JEL Classification: L1, L5, L65
Suggested Citation: Suggested Citation
Do you have negative results from your research you’d like to share?
Recommended Papers
-
Higher Prices from Entry: Pricing of Brand-Name Drugs
By Jeffrey M. Perloff, Valerie Y. Suslow, ...
-
By Ernst R. Berndt, Linda Tm Bui, ...
-
Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer Drugs
By Ernst R. Berndt, Robert S. Pindyck, ...
-
Generic Drug Industry Dynamics
By David Reiffen and Michael R. Ward
-
Hedonic Analysis of Arthritis Drugs
By Iain M. Cockburn and Aslam H. Anis
-
Longer Patents for Increased Generic Competition: The Waxman-Hatch Act after One Decade
By Henry G. Grabowski and John M. Vernon